Table 3. Copper, Zinc, Ceruloplasmin, d-ROMs and BAP.
| CEE (n = 15) |
Oral 17βE2 (n = 15) |
Transdermal 17βE2 (n = 15) |
||||
|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | |
| Copper (µg/dL) | 112.3 ± 14.0 | 152.1 ± 36.6** | 114.9 ± 18.0 | 125.6 ± 30.3 | 106.1 ± 13.5 | 99.7 ± 16.8 |
| Zinc (µg/dL) | 88.1 ± 13.2 | 80.8 ± 15.3 | 88.0 ± 11.3 | 84.7 ± 9.8 | 86.5 ± 10.7 | 81.3 ± 12.7 |
| Cu/Zn ratio | 1.31 ± 0.28 | 1.92 ± 0.52** | 1.32 ± 0.26 | 1.48 ± 0.30 | 1.25 ± 0.25 | 1.25 ± 0.27 |
| Ceruloplasmin (mg/dL) | 32.3 ± 5.2 | 42.5 ± 9.8** | 33.1 ± 6.5 | 35.2 ± 8.9 | 29.9 ± 3.8 | 27.8 ± 4.9* |
| d-ROMs (U.CARR) | 342.3 ± 43.5 | 501.5 ± 122.0** | 372.7 ± 79.5 | 399.3 ± 92.2 | 360.9 ± 73.5 | 308.1 ± 52.9* |
| BAP (µmol/L) | 2735 ± 383 | 2739 ± 193 | 2836 ± 538 | 2634 ± 267 | 2794 ± 352 | 2565 ± 304 |
Date are expressed as mean ± S.D.; CEE, conjugated equine estrogen; E2, estradiol; d-ROMs, derivatives of reactive oxygen metabolites; BAP, biological antioxidant potential;
*
P < 0.05
**
P < 0.01 vs pretreatment